Free Trial

Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application

 Iovance Biotherapeutics stock price

Key Points

  • Iovance’s lead product Lifileucel is an immunotherapy treatment that targets metastatic melanoma.
  • Immunotherapy uses a patient's immune system to detect and eliminate cancer cells.
  • The treatment focuses on bolstering one’s tumor-infiltrating lymphocytes (TILs) to treat solid tumors.
  • Iovance also seeks to expand its TILs treatment to small-cell lung and cervical cancer.
  • The FDA has granted a priority review with no advisory committee needed and a decision to come in Q4 2023.
  • 5 stocks we like better than Iovance Biotherapeutics

Iovance Biotherapeutics Inc. NASDAQ: IOVA shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Administration (FDA). The company submitted, and the FDA accepted, its Biologics License Application (BLA) for advanced melanoma. Iovance is a clinical-stage biotechnology company that develops novel immunotherapy treatments for various cancers. Immunotherapy is a form of personalized medicine. There are many types of immunotherapy, including monoclonal antibodies, immune checkpoint inhibitors and T-cell transfer, which is what Iovance uses.

T-Cell Transfer Immunotherapy

The T-cell transfer involves employing a patient's T-cells to help fight the cancer. This is also called adoptive cell therapy (ACT). Rather than focusing on trying to kill cancer cells like radiation and chemotherapy does, immunotherapy stimulates one’s natural immune responses to find and expunge cancer cells. Immunotherapy is better tolerated and more targeted than radiation and chemotherapy, which nukes all cells indiscriminately, healthy or cancerous.

What is Melanoma

Melanoma is a form of skin cancer that starts from melanocyte cells. These cells produce melanin which gives color to eyes, hair and skin. It can spread quickly and metastasize throughout the body if not detected early. When it spreads to the organs or lymph nodes, it's called metastatic melanoma, also known as stage IV melanoma. There are over 99,000 new cases of melanoma annually and over 7,600 deaths in the U.S.

Current  Melanoma Treatments

Surgery is the most common treatment if detected early as they attempt to remove the tumor. Chemotherapy can be used to kill cancer cells or slow their growth. Radiation treatment attempts to kill cancer cells with high-energy beams and is often used when its spreads to the brain, body and other body parts. Immunotherapy is another type of treatment. While immunotherapy has effectively treated blood cancers, there's still much contention regarding its effectiveness with solid tumors.


Lifileucel is a personalized immunotherapy comprised of a patient's tumor-infiltrating lymphocytes (TILs), a type of white blood cell believed to be critical in the immune response to cancer. TILs have receptors that recognize and bind to molecules in the cancer cells releasing proteins to kill them. Lifileucel is developed by extracting a patient's TILs, expanding them in the lab to make them special white blood cells and reinjecting them back into the patient. It helps the body to detect and attack cancer cells.

Market Potential

The total addressable market for Lifileucel is $1.2 billion, as the increasing number of metastatic melanoma patients is driving demand for immunotherapy treatments. The global melanoma market is expected to grow to $9.5 billion by 2030. Lifileucel can be combined with Keytruda as a first-line or a last-line of defense. Most significant is that the potential market for treating solid tumors is vast. Iovance estimates that 90% of all cancer cases are solid tumors, and 1.7 million new solid tumors occur annually in the U.S.

What’s Next?

Iovance has around $471 million in cash, which should be sufficient to cover its cash burn for the next 12 months. It has an action date of Nov. 25, 2023. It was previously granted a priority review and incidentally doesn't plan on an advisory committee meeting. The FDA decision's targeted date of action is November 25, 2023. It will be the first TIL approved for treatment in solid tumors if approved. The company is investigating other applications like non-small cell lung cancer and cervical cancer.


There’s always the possibility of a buyout from a larger pharmaceutical company already invested in melanoma treatments. Merck & Co. Inc. NYSE: MRK has been doing paired treatments of its Keytruda with Iovance and Moderna Inc. NASDAQ: MRNA. Bristol Myers-Squibb Co. NYSE: BMY has Opdivo, an FDA-approved treatment for progressive metastatic melanoma by blocking the PD-1 protein on t-cells. Pfizer Inc NYSE: PFE and Novartis AG NYSE: NVS also have FDA-approved targeted therapy and immunotherapy treatments for melanoma. A takeover possibility would likely be contingent on full FDA approval.

Iovance Therapeutics analyst ratings and price targets can be found on MarketBeat.

Iovance Therapeutics stock chart


Daily Ascending Triangle Breakout and Cup Formation

The daily candlestick chart for IOVA was in a descending triangle starting at $13.32 on Aug. 15, 2022, as it fell to a low range flat-bottom around $5.35 in April 2023. IOVA also started forming the cup lip line after peaking at $9.32 on November 11, 2022. IOVA staged a rally on the breakout through its daily market structure low (MSL) buy trigger of $6.28 on May 2, 2023. Shares rallied to retest the daily cup lip line at $9.32 before pulling back to form a handle at $7.12. The daily stochastic continues to fall through the 60-band. The daily 20-period exponential moving average (EMA) support sits at $7.47, followed by the 50-period MA at $6.51. Pullback supports are at $7.62, $7.12, $6.28 daily MSL trigger and $5.59.


Should you invest $1,000 in Iovance Biotherapeutics right now?

Before you consider Iovance Biotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iovance Biotherapeutics wasn't on the list.

While Iovance Biotherapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report
Jea Yu
About The Author

Jea Yu

Contributing Author

Trading Strategies

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Iovance Biotherapeutics (IOVA)
4.1959 of 5 stars
Novartis (NVS)
2.8267 of 5 stars
Bristol-Myers Squibb (BMY)
4.7062 of 5 stars
Merck & Co., Inc. (MRK)
4.0968 of 5 stars
$129.48+0.1%2.38%143.87Moderate Buy$133.00
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

Will FOMC Push Stocks Higher? Here’s What to Expect
Unlock Growth: Understanding Dividend Yield
Palantir Stock Excluded from S&P 500: Still a Buy?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines